Every year, an estimated 100-400 million people are infected with dengue virus worldwide, with about 400,000 annual deaths. It is one of the fastest-growing infectious diseases on the planet, fuelled by urbanisation and climate change pushing Aedes aegypti mosquitoes, the primary vector, into new territories. However, despite its scale, the tools available to fight dengue have remained frustratingly limited. Vaccines have struggled to work reliably across all four dengue serotypes, chemical repellents offer only modest protection, and community-based source reduction has shown little sustained impact in clinical trials. Scientists needed a fundamentally new approach.
In February 2026, a study published in the New England Journal of Medicine provided one a potential solution; and its central weapon is not a drug, a vaccine, or a pesticide. It is a bacterium. Additionally, the strategy involves releasing more mosquitoes, not fewer.
What Is Dengue and Why Is It So Hard to Fight?
Dengue is caused by a flavivirus transmitted almost exclusively by Aedes aegypti mosquitoes. What makes it particularly difficult to control is the existence of four distinct serotypes, DENV-1, 2, 3, and 4. Immunity to one serotype offers little protection against the others, and a second infection with a different serotype actually increases the risk of severe disease through a process called antibody-dependent enhancement, making vaccine development extraordinarily complex.
The CYD-TDV vaccine is being discontinued entirely, while newer candidates like TAK-003 and Butantan-DV have not demonstrated high efficacy across all four serotypes. Spatial repellents, chemical deterrents applied to living spaces, have shown only 20–40% protective efficacy in trials. For a disease infecting hundreds of millions annually, that is nowhere near enough.
The Wolbachia
Wolbachia pipientis is a naturally occurring intracellular bacterium, meaning that it lives inside cells rather than between them, and it is found in an estimated 50% of all insect species on Earth. It has co-evolved with insects for millions of years and is passed from mother to offspring through the cytoplasm of eggs, a process called maternal transmission.
The property that makes Wolbachia so useful in this context is a phenomenon called cytoplasmic incompatibility. When a Wolbachia-infected male mates with an uninfected female, something goes wrong at the moment of fertilisation as the eggs fail to develop and do not hatch. The Wolbachia modifies proteins associated with the sperm's chromatin (the complex of DNA and proteins that must be properly processed after fertilisation). In uninfected eggs, the cellular machinery needed to reverse these modifications is absent, causing the paternal chromosomes to fail to condense correctly during the first cell division. The embryo cannot develop, and the egg dies.
Critically, this incompatibility only works in one direction. Wolbachia-infected females can mate successfully with any male, infected or not, and produce viable offspring. This asymmetry is the key to the entire strategy: if you flood an environment with Wolbachia-infected males, uninfected wild-type females will increasingly mate with them rather than with uninfected males, producing non-viable eggs and progressively crashing the wild mosquito population.
The Singapore Trial
The study, conducted by Singapore's National Environment Agency, tested this strategy at a remarkable scale. Researchers divided 15 geographic population clusters across 12 square kilometres of urban Singapore into two groups. Eight clusters received regular releases of Wolbachia-infected male mosquitoes; seven received nothing and served as controls.
Researchers generated a localised Wolbachia-infected Aedes aegypti line by crossing a Singapore wild-type line with an infected line over six generations, ensuring complete maternal transmission and complete cytoplasmic incompatibility. The males were then exposed to low-dose irradiation before release, sterilising any accidentally included females and preventing the accidental establishment of a Wolbachia-infected population in the wild, while leaving male mating competitiveness intact. This combined approach is known as the Incompatible Insect Technique combined with Sterile Insect Technique, or IIT-SIT.
Releases were conducted twice weekly, at a rate of one to six mosquitoes per resident per week, on weekday mornings. The trial ran for 24 months, from 2022 to 2024. Importantly, only males were released, and as male mosquitoes do not bite, residents were never at any direct risk from the released insects.
The Results
Before the intervention began, mosquito populations were virtually identical across both groups. The average abundance, measured by the number of female mosquitoes trapped per trap, was 0.18 in the intervention clusters and 0.19 in the control clusters. By three months into the trial, the divergence was dramatic. In intervention clusters, average abundance had fallen to 0.041. In control clusters, it had actually risen to 0.27, which is more than six times higher than before.
The impact on dengue infection rates was equally significant. Among residents tested for dengue in intervention clusters, only 6% tested positive. In control clusters, the figure was 21%. The calculated protective efficacy of the intervention was 71–72%, and it held consistently across all age groups, both sexes, and across every calendar year of the trial. Crucially, because the intervention targets the mosquito rather than the virus itself, it worked against all dengue serotypes simultaneously, including dengue virus type 3, which was the dominant strain circulating during the trial period.
The results of this trial matter beyond dengue alone. Aedes aegypti is the same mosquito that transmits Zika, chikungunya, and yellow fever. A technology that suppresses Aedes aegypti populations would, in principle, reduce the transmission of all of these diseases simultaneously without targeting any specific virus or requiring a separate vaccine for each.
There are also important environmental advantages. Unlike chemical insecticides, which can have off-target effects on non-target species and disrupt ecosystems, this approach is highly specific as it only affects populations of Aedes aegyptithrough the mating dynamic. Public acceptance, often the hardest challenge for novel biological interventions, was also encouraging as 77% of residents in the trial areas expressed support for the releases.
Limitations
The trial was conducted in Singapore: a densely populated, highly urbanised city-state with extensive existing vector control infrastructure and sophisticated national dengue surveillance. These conditions are not universal, and whether the same efficacy would be achieved in rural or lower-resource settings remains an open question.
The technique also requires sustained, repeated releases. Released males have a half-life of just four days, meaning the programme cannot simply be initiated and left to run, it requires continuous production and deployment. The upfront costs are higher than conventional approaches, owing to the need for mosquito rearing facilities, sex separation, and irradiation equipment. Modelling studies suggest the approach becomes cost-effective at a protective efficacy threshold of around 40%, which this trial comfortably exceeded, but the infrastructure investment remains a barrier for many of the countries where dengue is most endemic.
Finally, the researchers note that wild mosquito migration into trial areas could not be entirely ruled out, and may have slightly attenuated the estimated protective effects.
Emily Jong